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Abstract  
Background: Kaposi’s sarcoma (KS), the most common AIDS related cancer, represents a 
major public concern in resource-limited countries. Single nucleotide polymorphisms within the 
Interferon lambda 3/4 region (IFNL3/4) determine the expression, function of IFNL4, and 
influence the clinical course of an increasing number of viral infections.  
Objectives: To analyze whether IFNL3/4 variants are associated with susceptibility to AIDS-
related KS among men who have sex with men (MSM) enrolled in the Swiss HIV Cohort Study 
(SHCS). 
Methods: The risk of developing KS according to the carriage of IFNL3/4 SNPs rs8099917 and 
rs12980275 and their haplotypic combinations was assessed by using cumulative incidence 
curves and Cox regression models, accounting for relevant co-variables.  
Results: KS was diagnosed in 221 of 2558 MSM Caucasian SHCS participants. Both 
rs12980275 and rs8099917 were associated with an increased risk of KS (cumulative incidence 
15% versus 10%, P=0.01 and 16% versus 10%, P=0.009 respectively). Diplotypes predicted to 
produce the active P70 form (cumulative incidence 16% versus 10%, P=0.01) but not the less 
active S70 (cumulative incidence 11% versus 10%, P=0.7) form of IFNL4 were associated with 
an increased risk of KS, compared to those predicted not to produce IFNL4.  
The associations remained significant in a multivariate Cox regression model after adjustment 
for age at infection, combination antiretroviral therapy, median CD4+ T-cell count nadir and 
CD4+ slopes (HR=1.43, 95% confidence interval 1.06-1.93, P=0.02 for IFLN P70 versus no 
IFNL4). 
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Conclusion: This study reports for the first time an association between IFNL3/4 polymorphisms 
and susceptibility to AIDS-related KS. 
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Introduction 
 
Kaposi’s sarcoma (KS) was initially described by Moritz Kaposi in 1872 as a rare and relatively 
indolent angioproliferative neoplasm affecting elderly men from countries surrounding the 
Mediterranean Sea (classical form of KS) [1]. Another form was described in sub-Saharan Africa 
in the 1950s, which affects middle aged adults and children (endemic form of KS) [2]. In 1981, a 
potentially fatal form of KS was described among young homosexual men as a characteristic 
feature of the AIDS epidemics (epidemic form of KS), a population in which it still represents 
one of the most common AIDS related cancer [3-8]. An invasive form can also affect patients 
with non-AIDS immune suppression, in particular solid organ transplant (SOT) recipients 
(iatrogenic form of KS, reviewed in [2]).  
 
While the four epidemiological forms of KS share the same histological characteristics [9] and 
are all subsequent to human herpes virus 8 (HHV-8) infection [10, 11], the development of 
distinct clinical features seems to rely on a combination of host and environmental factors. While 
HIV- or drug-related immune suppression is inherent to the epidemic and iatrogenic forms 
(AIDS and SOT), genetic predisposition may be required for the classical (Mediterranean and 
Jewish ancestry) [12-14] and endemic forms (Sub-Saharan Africa) [15]. Hormonal factors [16-
19] have been proposed to explain the male predominance of all forms of Kaposi sarcoma. 
Environmental conditions relative to potential routes of infection (soil, animal vectors) have been 
proposed to influence susceptibility to different forms of KS [20-25]. While viral factors may 
influence clinical presentation, evidence for a definite link between a specific subtype strain and 
a KS type is still lacking [26-29]. 
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Several investigators have analyzed the role of host genetic factors in susceptibility to KS within 
a given populations at risk. The most relevant was a polymorphism within the IL-6 promoter, 
which was consistently more frequent among KS patients versus controls in two cohorts of AIDS 
patients [30, 31] and a small cohort of SOT patients [32]. Polymorphisms in other candidate 
genes (e.g. MHC- or cytokines/chemokines-related genes) were associated with KS in studies of 
AIDS patients [31, 33-35] and two studies including patients with the classical form of KS [36, 
37]. 
Single nucleotide polymorphisms (SNPs) in the region encoding for interferon lambda 3 (IFNL3 
previously named IL-28B) and interferon lambda 4 (IFNL4) represent major factors in the ability 
of individuals to clear HCV [38-41]. They determine different haplotypic combinations 
(diplotypes) based on their capacity to produce IFNL4, i.e. no production versus production as an 
active P70 or less active S70 form [42-44]. IFNL3/4 SNPs are increasingly known to influence 
the susceptibility to or the clinical course of infections due to viruses other than HCV, including 
herpes viruses such as CMV and EBV [45-47]. Here, we hypothesize that IFNL3/4 
polymorphisms influence the risk to develop KS in AIDS patients.  
 
Material and Methods 
 
Study patients. The Swiss HIV Cohort Study (SHCS) is an ongoing multicenter prospective 
study of HIV-infected patients enrolled at seven major Swiss hospitals and their local affiliated 
centers since 1988 [48]. For the present study, Caucasian men who have sex with men (MSM) 
with available DNA for genotyping and a written informed consent for genetic studies were 
included. In order to account for the time at risk, only patients with an estimated date of HIV 
infection were selected [49]. Demographic characteristics including age, duration of HIV 
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infection, CD4 T-cell count nadir, other opportunistic infections, HIV maximal viral load and 
HAART use were extracted from the SHCS clinical database. Kaposi sarcoma was defined 
according to predefined clinical and histological criteria.  
SNP genotyping. Genomic DNA isolated either from blood or cell pellets was genotyped for 
haplotype tagging SNPs rs8099917 and rs12980275 using a customized GoldenGate Genotyping 
Assay on Veracode® platform (Illumina ®, San Diego, CA, USA). These SNPs were used as 
surrogates for rs368234815 and rs117648444, respectively, based on  previously published LD 
values, which were shown to determine the three main diplotypic forms of IFNL4. (refs) 
Statistical analysis. Statistical analyses were performed using Stata (version 14.2, StataCorp LP, 
College Station, TX). Hardy-Weinberg equilibrium (HWE) was verified using the program 
genhw implemented in Stata. Haplotypes were inferred using the Phased and grouped according 
their ability to express the different forms of IFNL3/4 as described previously [43]. The 
association of IFNL3/4 polymorphisms with Kaposi’s sarcoma was assessed by 25 year-
cumulative incidence curves as well as uni- and multivariable Cox regression models, using the 
estimated date of HIV infection as a starting point, with censoring at death and/or lost follow-up. 
Stepwise (i.e. backward) regression (P<0.1) was used to determine which variables were 
independently associated with the endpoint. The proportional hazard assumption was verified by 
using the stphtest command implemented in Stata. Estimated dates of HIV infection and CD4 
slopes in both incident and prevalent cases were obtained by using a joint back calculation model 
as described previously [50].  
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Results  
The study included 2558 MSM patients among whom 221 developed KS (8.6%, Supplementary 
Table 1, http://links.lww.com/QAD/B360). Considering the whole patient, the median age at 
estimated date of HIV infection was 34 (interquartile range, IQR=13). The median CD4+ T cells 
nadir was 181 cells/mm3 (IQR=174) and the maximal HIV RNA viral load 5.12 log10 copies/ml 
(IQR=0.85). Most individuals started HAART therapy during follow-up (97%). An active HBV 
infection was recorded in 10% of patients and HCV serology was positive in 8%. 
 
The minor allele frequencies (MAFs) of IFNL3/4 rs12980275 and rs8099917 were 0.30 and 
0.20, respectively, and both were at HWE. Carriage of rs12980275 and rs8099917 were both 
associated with an increased risk of KS (CI 15% versus 10%, P=0.01 and CI 16% versus 10%, 
P=0.009, respectively, Figure 1). Diplotypes predicted to produce the active P70 form of IFNL4, 
but not those predicted to produce the less active S70 form were associated with an increased 
risk of KS, compared to diplotypes not producing IFNL4 (CI 16% versus 10%, P=0.01 and CI 
11% versus 10%, P=0.7, respectively)  
 
The association between IFNL4P70-producing diplotypes and KSA remained significant in a 
multivariate Cox regression model, accounting for age at infection, HAART, median CD4+ T-
cell count nadir and CD4+ slopes [(hazard ratio 1.43, 95% confidence interval (CI) 1.06-1.93, 
P=0.02), Table 1].  
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Discussion 
Polymorphisms in the region encoding for IFNL3 and 4 have been identified for their major role 
in the ability of individuals to clear HCV. Increasing evidence suggests that such polymorphisms 
can also influence the clinical course of infections due to viruses other than HCV [51, 52], in 
particular those from  the Herpesviridae family (CMV [45, 46], EBV [47] and HSV [53]). In this 
study, we report for the first time an association between IFNL3/4 polymorphisms and 
susceptibility to Kaposi’s sarcoma among HIV-infected MSM.  
 
An increasing number of in vitro studies support the role of IFNL in the immunopathogenesis of 
viral infections due to viruses other than HCV. A series of cell culture-based models have shown 
that IFNL3/4 controls the replication of viruses such as human [54] and murine CMV [55], 
HSV2 [56], HBV [57], dengue virus [58], human metapneumovirus (hMPV) [59], influenza 
virus [60-62], lymphocytic choriomeningitis virus (LCMV) [63] and Sendai virus [64]. While no 
studies have analyzed the direct role of IFNL on HHV-8 replication, the involvement of IFNL in 
its immunopathogenesis is supported indirectly by at least two studies. Those showed that HHV-
8 can inhibit IFN transcription by the production of interferon regulatory factor (IRF) 
homologues as well as block the expression of interferon stimulating genes (ISGs) through JAK-
STAT pathway interference [65, 66].  
 
Haplotypic combinations predicted to produce the P70 active, but not the S70 less active form of 
IFNL4, were associated with an increased risk of KS. This is consistent with the association 
reported in other viral infections; SNPs encoding or tagging the P70 IFNL4 induce a higher 
susceptibility to HCV [42, 44], CMV [45, 46], EBV [47] and HSV [53]. This paradoxical effect 
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of IFNL4 may rely on at least 3 different mechanisms. First, IFNL4 may compete with the other 
IFNLs through a mechanisms involving the overexpression of its IFNLR1 subunit [67]. Second, 
IFNL4 may induce a refractory state of the pathway due to persistent ISG expression [43]. Third, 
individuals expressing the active form of IFNL4 may in return produce lower amount of IFNL3, 
with subsequent reduced ISG expression [42, 68, 69]. The resulting balance between IFNL3 and 
IFNL4 expression may be particularly relevant in KS lesions, given the presence of numerous 
recruited plasmacytoid dendritic cells (pDC), which represent the most important producer of 
these cytokines [70]. 
 
Beyond antiviral properties, IFNLs may also exert anti-tumoral activities including a growth 
inhibitory effect and apoptosis of tumor cells, as recently described in culture of melanoma [71], 
lung adenocarcinoma [72, 73], neuroendocrine cancer [74], colorectal carcinoma [75], 
esophageal carcinoma [76] and hepatocellular carcinoma [77] cells or in mouse models of 
melanoma [78], colon adenocarcinoma [78] and fibrosarcoma [79]. In humans, the expression of 
IFNL1 has been negatively correlated with the progression of cervical cancer due to papilloma 
virus [80], suggesting a potential role of this cytokine in cancer immunity. Altogether, these data 
suggest that polymorphisms in IFNLs may not only influence the immunity against HHV-8, but 
also immunity against KS cancer cells.  
Like most genetic association studies, our study performed on HIV-infected MSM is constrained 
by some limitations. Data on HHV-8 sero-prevalence are not available in the SHCS cohort, 
thereby preventing analyses limited to patients with Kaposi sarcoma but excluding HHV-8 
positive individuals who did not develop KS. This limitation may be at least in part compensated 
by the fact that the prevalence of HHV-8 among MSM is elevated [81, 82] and that the 
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prevalence of KS and HHV-8 is very well correlated in HIV-infected populations [83-85]. Most 
likely the currently chosen analytic approach would under- but not overestimated the effect of 
IFL polymorphisms. 
 
In summary, our data show an association between IFNL3/4 polymorphism and the development 
of KS among HIV+ MSM patients. This new finding confirms that IFNLs mediate anti-viral 
responses against a growing range of viruses. 
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Table 1. Independent risk factors associated with KS among MSM. 
 
 Univariate Multivariate 
Variable HR (95% CI)1 P HR (95% CI) P 
Age at estimated  
date of infection  1.01 (1.00-1.03) 0.07 1.05 (1.00-1.11) 0.07 
CD4+ nadir2  
(sqrt transformed,continuous) 0.99 (0.99-1.00) <0.001 1.00 (0.99-1.00) <0.001 
CD4+ slope3 (continuous) 0.69 (0.58-081) <0.001 0.84 (0.70-1.02) 0.07 
Maximal HIV RNA load 
(continuous) 1.21 (1.01-1.44) 0.04 1.02 (0.84-1.24) 0.85 
HAART (time-dependant covariate) 
2.96 (0.74-
11.93) 0.13 0.38 (0.26-0.55) <0.001 
HCV co-infection4 0.92 (0.55-1.53) 0.75   
Active HBV infection5 1.32 (0.78-2.24) 0.30   
SNPs     
IFNL3/4 rs12980275 
(AA versus AG or GG) 1.36 (1.04-1.77) 0.03   
IFNL3/4 rs8099917 
(TT versus TG or GG) 1.40 (1.07-1.82) 0.01   
     
Diplotypes     
No IFNL4 Reference  Reference  
IFNL4 P70 1.40 (1.05-1.87) 0.02 1.43 (1.06-1.93) 0.02 
IFNL4 S70 1.09 (0.74-1.61) 0.67 1.06 (0.69-1.60) 0.80 
     
 
HR stands for hazard ratio; CI, confidence interval; HAART, highly active antiretroviral therapy; 
HCV, hepatitis C virus; HBV, hepatitis B virus. Stepwise (i.e. backward) regression (P<0.2) was 
used to determine which variables were independently associated with the endpoint. 
 
1 The proportional hazard assumption was verified for all variables with the exception of CD4+ 
slope. However, the association between IFNL4P70 and KS was similar when CD4+ slope 
was removed from the multivariate model (HR 1.33, 95% CI 1.07–1.65, P=0.01) 
2 The CD4+ nadir square root was used to obtain a normally distributed variable  
3 Rate of CD4+ depletion in the absence of HAART 
4 Reflected by HCV serology 
5 Defined by the presence of HBsAg in the blood 
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Figure legend 
 
Figure 1. Cumulative incidence of Kaposi’s sarcoma according to IFNL4 rs12980275 (A), 
IFNL3/4 rs8099917 (B), IFNL4P70 (C) in MSM participants of the SHCS. The estimated date of 
HIV infection was used as a starting point with censoring at death or lost follow-up. (n) indicates 
the number of patients with KS in each group of patients. P values were calculated by log-rank 
test, dominant mode. 
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